Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Extracellular potassium is a vital cation essential for the physiological function of excitable tissues, including the myocardium and skeletal muscle (StatPearls, 2023). It plays a central role in establishing the resting membrane potential and facilitating the repolarization phase of action potentials (National Center for Biotechnology Information, 2023). Under normal conditions, potassium levels are strictly maintained within a narrow range, typically 3.5 to 5.0 mEq/L, through renal excretion and the activity of the Na+/K+-ATPase pump (Mayo Clinic, 2023). Dysregulation of this balance, most notably hyperkalemia, is a frequent complication in patients with chronic kidney disease or heart failure, often exacerbated by the use of renin-angiotensin-aldosterone system (RAAS) inhibitors (American Heart Association, 2022). Severe hyperkalemia poses a significant risk for lethal cardiac arrhythmias and sudden cardiac death (National Kidney Foundation, 2023). Pharmacological intervention involves the use of potassium binders, such as Patiromer or Sodium zirconium cyclosilicate, which sequester the ion in the gastrointestinal tract to promote fecal excretion (FDA, 2015; FDA, 2018). Additionally, acute management may involve shifting potassium from the extracellular to the intracellular space using agents like insulin or beta-2 adrenergic agonists (StatPearls, 2023). Monitoring serum potassium levels is the standard clinical approach to assess the efficacy and safety of these therapeutic interventions (Journal of the American Society of Nephrology, 2020).
Drugs targeting extracellular potassium primarily work through three mechanisms: gastrointestinal sequestration via cation exchange to promote fecal excretion (potassium binders), redistribution from the extracellular to the intracellular compartment via stimulation of the Na+/K+-ATPase pump (insulin or beta-2 agonists), or enhancement of renal excretion (loop or thiazide diuretics).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Extracellular potassium (K+).